Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma
← catalyst calendarNCT03969004 · readout in 505 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
415actual
Sites
166
Countries
Australia, Belgium, Brazil +13
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2019-06-04 | actual | When the study began enrolling |
| Primary completion | 2028-01-07 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-07 | estimated | The whole study's end, after follow-up |
| First posted | 2019-05-31 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Cutaneous Squamous Cell Carcinoma
Interventions
- Drug: Cemiplimab — also filed as REGN2810, Libtayo
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFDFS defined as time from randomization to the first documented disease recurrence (local, regional and/or distant); or death due to any cause.
measured Up to 54 months
Publications
- PMID 40454639 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed